Lunai Bioworks Inc. (RENB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RENB
- Company Lunai Bioworks Inc.
- Price $1.42
- Changes Percentage 0
- Change 0
- Day Low $1.19
- Day High $1.42
- Year High $21
- Year Low $1.12
- Market Cap $32,915,951
- Price Avg 50 EMA (D) $1.96
- Price Avg 200 EMA (D) $4.41
- Exchange NASDAQ
- Volume 808,780
- Average Volume 218,513
- Open $1.19
- Previous Close $1.42
- EPS -10.8
- PE -0.13
- Earnings Announcement 2026-02-17 21:00:00
- Shares Outstanding $23,180,247
Company brief: LUNAI BIOWORKS INC. (RENB )
- Healthcare
- Biotechnology
- Hon. Mark R. Dybul M.D.
- https://www.renovarobio.com
- US
- N/A
- 02-07-2018
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.